Ropes & Gray represented Sanofi and EQT Life Sciences in their investment in SpliceBio’s $135 million Series B financing. SpliceBio is a Barcelona-based clinical-stage genetic medicines company with a proprietary protein splicing platform. The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease.
The Ropes & Gray team included venture capital and emerging companies counsel David Dowling, IP transactions partner Melissa Rones, IP transactions counsel Ryan Murphey, strategic transactions associate Jennifer Eppinger, and venture capital and emerging companies partner Rajarshi Banerjee.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.